Trainee Pearls

The EBMT Trainee Committee
  • 0.0 (0)
  • MEDICINA
  • CADA SEMANA

Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.

  1. 29/10/2023

    #18 Jurjen Versluis: Transplant for high-risk MDS

    Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. https://pubmed.ncbi.nlm.nih.gov/37607457/ ALSO AS VIDEO ON https://youtu.be/JbHS_-2sJQc CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

    21 min

  2. 05/09/2023

    #17 Nathanial Anderson: Signatures and persistence of CAR-T cells

    In this study, Nathanial and colleagues systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. Article: https://www.nature.com/articles/s41591-023-02415-3 As VIDEO on https://youtu.be/z_aJgRHpEaI

    23 min

  3. 14/07/2023

    #16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma

    Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://pubmed.ncbi.nlm.nih.gov/37414060/ ALSO AS VIDEO ON https://youtu.be/Ymgg22roWGU CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

    17 min

  4. 20/05/2023

    #15 Francesca del Bufalo: CAR-T cells for neuroblastoma

    Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. In an academic, phase 1–2 clinical trial, the investigators enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). https://www.nejm.org/doi/full/10.1056/NEJMoa2210859 ALSO AS VIDEO ON YOUTUBE https://youtu.be/o1DVDcrrHFA CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

    24 min

  5. 05/12/2022

    #12 Justin Loke: Cytogenetics and TP53 in BMT for AML

    The presence of TP53 mutations is associated with an unfavorable outcome  in patients allografted for acute myeloid leukemia (AML), leading some  to question the benefit of an allogeneic stem cell transplantation  (allo-SCT) for this patient group, although this has not been studied in  a large cohort.  Article: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34268  ALSO AS AUDIO ON https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132 https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

    15 min

  6. 22/09/2022

    #11 Ferran Nadeu: Early seeding of Richter transformation

    Richter transformation (RT) is a paradigmatic evolution of chronic  lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma  conferring a dismal prognosis. The mechanisms driving RT remain largely  unknown.   Article: https://www.nature.com/articles/s41591-022-01927-8   ALSO AS AUDIO ON https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132  https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y   CONNECT WITH US  https://twitter.com/TheEBMT_Trainee  https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

    26 min

  7. 23/08/2022

    #10 Elsa Bernard: IPSS-M in MDS

    Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk stratification of patients with MDS. Combining genomic profiling with hematologic and cytogenetic parameters, the IPSS-M improves the risk stratification of patients with MDS and represents a valuable tool for clinical decision-making. CONNECT WITH US  https://twitter.com/TheEBMT_Trainee  https://www.ebmt.org/trainee-committee  https://twitter.com/CarmeloGurnari

    29 min

  8. 07/07/2022

    #9 Alice Bertaina: Stem cell-kidney transplant for SIOD

    Schimke immuno-osseous dysplasia (SIOD) is a multisystem disorder that  is inherited in an autosomal recessive pattern. It usually manifests  first with growth failure. Other features of the disease are generally  noted in the ensuing evaluation of the growth failure or develop in the  following years.    Article:  https://www.nejm.org/doi/10.1056/NEJMoa2117028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed    ALSO AS AUDIO ON  https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132  https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y   YOUTUBE  "EBMT Trainees" CONNECT WITH US  https://twitter.com/TheEBMT_Trainee  https://www.ebmt.org/trainee-committee  https://twitter.com/CarmeloGurnari

    28 min
Ver todo (16)

Acerca de

Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.

Información

  • Creador
    The EBMT Trainee Committee
  • Años de actividad
    2021 - 2023
  • Episodios
    16
  • Clasificación
    Apto
  • Copyright
    © The EBMT Trainee Committee
  • Mostrar sitio web
    Trainee Pearls